|
1
|
Brown P, Pieters R and Biondi A: How I
treat infant leukemia. Blood. 133:205–214. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deschler B and Lubbert M: Acute myeloid
leukemia: Epidemiology and etiology. Cancer. 107:2099–2107. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown P: Treatment of infant leukemias:
Challenge and promise. Hematology Am Soc Hematol Educ Program.
2013:596–600. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Newell LF and Cook RJ: Advances in acute
myeloid leukemia. BMJ. 375:n20262021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tasian SK, Loh ML and Hunger SP: Childhood
acute lymphoblastic leukemia: Integrating genomics into therapy.
Cancer. 121:3577–3590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doss CG and Sethumadhavan R: Investigation
on the role of nsSNPs in HNPCC genes-a bioinformatics approach. J
Biomed Sci. 16:422009. View Article : Google Scholar
|
|
8
|
Wang S, Wu Z, Li T, Li Y, Wang W, Hao Q,
Xie X, Wan D, Jiang Z, Wang C and Liu Y: Mutational spectrum and
prognosis in NRAS-mutated acute myeloid leukemia. Sci Rep.
10:121522020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lampson BL and Brown JR: Are BTK and PLCG2
mutations necessary and sufficient for ibrutinib resistance in
chronic lymphocytic leukemia? Expert Rev Hematol. 11:185–194. 2018.
View Article : Google Scholar
|
|
10
|
Turrubiartes-Martinez E, Bodega-Mayor I,
Delgado-Wicke P, Molina-Jiménez F, Casique-Aguirre D,
González-Andrade M, Rapado I, Camós M, Díaz-de-Heredia C, Barragán
E, et al: TYK2 Variants in B-Acute Lymphoblastic Leukaemia. Genes
(Basel). 11:14342020. View Article : Google Scholar
|
|
11
|
Haferlach T, Nagata Y, Grossmann V, Okuno
Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T,
et al: Landscape of genetic lesions in 944 patients with
myelodysplastic syndromes. Leukemia. 28:241–247. 2014. View Article : Google Scholar
|
|
12
|
Wang K, Zhou F, Cai X, Chao H, Zhang R and
Chen S: Mutational landscape of patients with acute myeloid
leukemia or myelodysplastic syndromes in the context of RUNX1
mutation. Hematology. 25:211–218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumar AR, Yao Q, Li Q, Sam TA and Kersey
JH: t(4;11) leukemias display addiction to MLL-AF4 but not to
AF4-MLL. Leuk Res. 35:305–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen C, Yu W, Alikarami F, Qiu Q, Chen C,
Flournoy J, Gao P, Uzun Y, Fang L, Davenport JW, et al: Single-cell
multiomics reveals increased plasticity, resistant populations and
stem-cell-like blasts in KMT2A-rearranged leukemia. Blood.
139:2198–2211. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rice S, Jackson T, Crump NT, Fordham N,
Elliott N, O'Byrne S, Fanego MDML, Addy D, Crabb T, Dryden C, et
al: A human fetal liver-derived infant MLL-AF4 acute lymphoblastic
leukemia model reveals a distinct fetal gene expression program.
Nat Commun. 12:69052021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schwaller J: MLL-AF4+ infant leukemia: A
microRNA affair. Blood. 138:2014–2015. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laetsch TW, Maude SL, Balduzzi A, Rives S,
Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M,
Phillips CL, et al: Tisagenlecleucel in pediatric and young adult
patients with Down syndrome-associated relapsed/refractory acute
lymphoblastic leukemia. Leukemia. 36:1508–1515. 2022. View Article : Google Scholar
|
